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Abstract 1 
Background/Objectives: Adaptive immunity has been implicated in adipose tissue 2 
inflammation, obesity and its adverse metabolic consequences. No obesity-related autoantigen 3 
has yet been identified, although heat shock protein 60 (HSP60) has been implicated in other 4 
autoimmune diseases. 5 
Subjects/Methods: We investigated whether feeding a high fat diet to C57BL/6J mice would 6 
cause autoimmunity to HSP60 and whether immunomodulation with peptides from HSP60 7 
would reverse the resulting obesity or metabolic dysfunction.  8 
Results: Obese mice had higher circulating levels of HSP60 associated with increased T-9 
lymphocyte proliferation responses and the emergence of circulating IgG1 and IgG2c antibody 10 
levels against HSP60. Treatment with escalating doses of a mixture of three proven 11 
immunomodulatory HSP60 peptides did not reduce weight but completely reversed the increase 12 
in VLDL/LDL levels and partially reversed the glucose intolerance in obese mice.   13 
Conclusions: Obese mice mount an autoimmune response to HSP60, which partly underlies the 14 
resulting metabolic disturbances. 15 
 16 
Key words: Autoimmunity, heat shock proteins, glucose tolerance test, lipoproteins, mice, 17 
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Abbreviations: AT, adipose tissue; HSP60, heat shock protein 60; ND, normal diet; HFD, high 20 
fat diet; Th(1/2), Thelper(1/2) lymphocyte; Treg, regulatory T lymphocyte; SVF, stromal 21 
vascular fraction 22 
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Introduction 1 
Obesity is increasing worldwide, accompanied by rising levels of type-2 diabetes and the 2 
metabolic syndrome, fatty liver disease, breast and colon cancer, musculoskeletal disorders and 3 
cardiovascular diseases, including atherosclerosis and stroke 1, 2. Many harmful effects of obesity 4 
have been attributed to adipose tissue (AT) inflammation 3, with both innate and adaptive 5 
immunity implicated 4.  The evidence that T-lymphocytes contribute to AT inflammation 6 
includes: 1) T cells accumulate in AT even before macrophages 5-7.  2) Restricted Vα repertoires 7 
imply antigen-specific clonal expansion 8.  3) Deletion of MHC Class II molecules globally or 8 
on macrophages reduces obesity, insulin resistance and AT inflammation 9, 10.  5) Conversely, 9 
enhancement of antigen-presenting cell function favours AT inflammation and promotes insulin 10 
resistance 11. This evidence suggests an autoimmune component in obesity but no culprit 11 
autoantigens have so far been identified. 12 
HSP60 is an evolutionarily-conserved mitochondrial chaperonin  that can translocate to 13 
the cytosol and cell membrane and be released into the circulation under conditions of stress 12. 14 
HSP60 has been associated with the autoimmune component of several inflammatory diseases, 15 
including atherosclerosis 12. More recently, release of HSP60 from AT was demonstrated as well 16 
as its ability to cause insulin resistance and pro-inflammatory cytokine (TNF-α, IL-6 and IL-8) 17 
release by adipocytes 13. Also, circulating HSP60 levels were found higher in obese individuals 18 
than lean controls 13. All these observations make HSP60 a candidate autoantigen in obesity, 19 
although this has not yet been demonstrated.  We therefore investigated whether high fat diet 20 
(HFD) feeding gives rise to autoimmunity against HSP60 in mice and whether 21 
immunomodulation with HSP60-specific peptides can reduce obesity or the related metabolic 22 
impairment.  23 
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Materials and Methods  1 
More detail is given in the Supplementary Methods file available at the International Journal 2 
of Obesity’s website. Briefly: C57BL/6J mice (6 weeks old) purchased from Charles River 3 
Laboratories were fed normal chow (ND) or a HFD supplemented with 21% lard and 0.15% 4 
cholesterol (Special Diets Services) for 16-20 weeks to induce obesity. For peptide treatment, 5 
6 week old mice were pre-dosed subcutaneously with HSP60 peptides (GL Biochem, 6 
Shanghai) starting at 0.1 µg/mouse. The dose was increased 10 fold every week up to 100 7 
µg/mouse, which was given weekly 3 more times, then every two weeks until the end of study. 8 
HFD was started at 11 weeks of age (after the third top dose) and lasted for 20 weeks 14 followed 9 
by euthanasia by cervical dislocation under Home Office Licence 70/22957.  The Guide for 10 
the care and use of laboratory animals, Eighth edition (2011) 11 
(http://grants.nih.gov/grants/olaw/guide-for-the-care-and-use-of-laboratory-animals.pdf) was 12 
followed. Procedures were carried out under Home Office Licences 30/3064 and 70/22957. All 13 
animals survived until culled and were included in the analysis. 14 
 15 
After euthanasia, epididymal fat pads were collected, weighed and the stromal vascular 16 
fraction (SVF) was isolated by collagenase digestion.  For analysis of macrophage populations, 17 
1 million SVF cells were examined by flow cytometry analysis using antibodies against 18 
CD11b, F4/80, CD11c and CD206. T-cell populations were analysed using antibodies against 19 
CD45, CD3ε, CD4, CD25 and FoxP3. 20 
Serum HSP60 levels were measured with a mouse HSP60 ELISA (NeoScientific). 21 
Serum anti-HSP60 antibody levels were measured with a custom-made ELISA using 22 
recombinant, endotoxin-depleted murine HSP60 protein (Enzo Life Sciences) bound to Nunc 23 
Immuno MaxiSorp 96 well plates.  For the HSP60 reactive T cell proliferation assay, total cell 24 
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pellets from homogenized spleens were pulsed with 3H-thymidine for 18 hours after pre-1 
treating with buffer control, recombinant HSP60 or peptides. 2 
 Glucose tolerance tests were performed after 16 weeks of ND or HFD. After 6 hours 3 
fast, 2 g/kg body weight of glucose was injected intraperitoneally and glucose concentration in 4 
blood from tail snips was measured 0, 15, 30, 60, and 90 minutes later. Insulin tolerance test 5 
was conducted one week later. After 4 hours fast, rapid acting human insulin (NovoRapid; 6 
Novo Nordisk A/S) was injected intraperitoneally to give a final dose of 1 U/kg body weight. 7 
Blood glucose was measured at the same time points. Mouse Ultrasensitive Insulin ELISA kit 8 
(Alpco) was used to determine fasting insulin levels. 9 
For normally-distributed variables (Kolmogorov-Smironov test), a two-tailed, unpaired 10 
Student’s t-test was used to determine significant differences between 2 means. For multiple 11 
comparisons, a one-way ANOVA or two-way ANOVA was performed, as appropriate, 12 
followed by a Bonferroni correction. Differences were considered significant if p < 0.05. 13 
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Results 1 
 2 
Increased circulating HSP60 levels, antibodies against HSP60, and T-cell responses to HSP60 3 
in HFD fed C57BL/6J mice 4 
C57BL/6J mice fed HFD for 16 weeks were 3g heavier than ND mice (Fig. 1A) and 5 
their epididymal fat pads were almost 3 times heavier (Fig. 1B). Plasma levels of LDL/VLDL 6 
were significantly increased (74%) by HFD, although HDL levels were unaltered (Fig. 1C). 7 
HFD significantly increased circulating HSP60 levels by 12% (Fig. 1D), suggesting that 8 
obesity is a stress factor capable of stimulating HSP60 release. 9 
As evidence for an autoimmune reaction to HSP60, recombinant HSP60 increased 10 
splenic T lymphocyte proliferation relative to buffer controls by 20-40% more in HFD than 11 
ND mice. This increase was significant at 0.1 µg/ml and 10 µg/ml and it was at borderline 12 
significance (p=0.063) at 1.0 µg/ml concentration (Fig. 1E).  The response to HSP60 was much 13 
weaker than the positive control ConA (13 fold, not shown), not surprisingly because the mice 14 
were not hyper-immunized. Circulating anti-HSP60 levels were undetectable in ND mice but 15 
HFD significantly elevated both anti-HSP60 IgG1, which is mainly dependent on Thelper2 16 
(Th2) lymphocytes, and IgG2c, which is driven by Th1 lymphocytes 15 (Fig. 1F). Differences 17 
between HFD and ND mice were highly significant above 1/16 dilution; much lower than 18 
expected for hyper-immune serum (typically >1/1000). Clearly, short periods of obesity 19 
triggered autoimmunity against murine HSP60, albeit at low-level.  20 
 21 
Effect of HSP60 peptide treatment on obesity and related metabolic dysfunction. 22 
To investigate the impact of HSP60 autoimmunity, we used subcutaneous HSP60 23 
peptide treatment with a combination of equal concentrations of three peptides known to cause 24 
favourable immunomodulation in models of autoimmune diabetes or atherosclerosis. These 25 
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were vlgggcallrcipaldslkpaned 16, aelkkqskpvt 17 and dgealstlvlnrlkvg 18. Each of these peptides 1 
had good solubility in water (results not shown).  We used a dose escalation protocol that has 2 
proved safe and effective against experimental autoimmune encephalomyelitis 14. 3 
HSP60 peptide treatment did not reverse HFD-induced weight gain (Fig. 2A) or the 4 
increase in epididymal fat mass (Fig. 2B), which were greater in this experiment owing to the 5 
longer period of HFD feeding.  However, peptide treatment reversed the significantly increased 6 
circulating LDL/VLDL levels in HFD mice (Fig. 2C). 7 
Glucose tolerance was significantly impaired in HFD compared to ND mice. HSP60 8 
peptide treatment rendered HFD mice significantly more glucose tolerant, although not as 9 
tolerant as ND mice (Fig. 2D).  Fasting insulin levels were elevated to the same degree relative 10 
to ND (0.64±0.05) by HFD, irrespective of peptide treatment (1.01±0.22 and 1.18±0.22) and 11 
could not account for the improved glucose tolerance. Insulin sensitivity, measured in an 12 
insulin tolerance test, was also similar in ND, HFD and peptide treatment groups (Fig. 2E).  13 
To investigate whether HSP60 peptide treatment suppressed obesity-associated 14 
inflammation, we subjected SVF cells to flow cytometry. We recorded a significant increase 15 
in macrophages (Fig. 2F), no change in total CD4+ or CD4- T-lymphocytes (not shown) and a 16 
decrease in Treg cells (Fig. 2G) in HFD compared to ND mice but there was no effect of HSP60 17 
peptide treatment (Fig. 2F, G).  We also did not observe any difference in splenic T-cell 18 
proliferation responses to recombinant HSP60 in HFD-fed mice with and without HSP60 19 
peptide treatment. Nor did we find any difference in the levels of IL2, IL4, IL6, IL10, IL17, 20 
IFNγ or TNFα released spontaneously or in response to HSP60 challenge (results not shown).  21 
However, HSP60 peptide treatment increased the titre of anti-HSP60 IgG1 (Fig. 2H) but not 22 
IgG2c antibodies (Fig. 2I), which implies an enhancement of Th2 driven antibody production.  23 
 24 
  25 
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Discussion 1 
 2 
An autoimmune component of obesity has been postulated 8, 9 (see Introduction) but 3 
our study is the first to identify a contributing autoantigen.  Obese mice clearly mounted a weak 4 
autoimmune response to HSP60 at both the T and B cell levels after a short period of HFD. 5 
Consistent with this, lean humans have antibodies to HSP60, presumably arising from other 6 
stressors 12, but the level of autoantibodies is increased by obesity that is clearly much more 7 
prolonged than in our mice 13. Moreover, we could reverse the hypercholesterolaemic effect of 8 
HFD and partially improve glucose tolerance with immunomodulatory HSP60 peptide 9 
treatment, implying that autoimmunity to HSP60 contributed to the metabolic disturbances 10 
caused by obesity, despite weight not being reduced. A similar decoupling of obesity and 11 
metabolic disturbances has been noted in other studies when suppressing adaptive immunity, 12 
for example in RAG-1 deficient mice, which lack mature T and B lymphocytes 8. Given 13 
observations that LDL production is increased by obesity 19 and that HSP60 autoimmunity 14 
contributes to atherosclerosis 12, the reduction in LDL levels achieved by HSP60 peptide 15 
treatment is of interest.  A recent study showing that regulatory T-cells can reduce the levels 16 
of blood cholesterol in low density lipoprotein deleted mice might provide a mechanisms for 17 
our results 20, but this requires further investigation. 18 
HFD increased AT macrophages and decreased Treg as previously reported by others 19 
(reviewed by Lolmede et al.4) but we did not see any changes with HSP60 peptide treatment. 20 
Neither did we find any influence of peptide-induced splenic T-cell proliferation or cytokine 21 
release. We did, however, see a switch towards Th2 driven IgG1 production, which implies 22 
that HSP60 peptide treatment caused immunomodulation rather than immune tolerization, 23 
which will require more extensive investigation.  In summary, we showed for the first time that 24 
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low-level autoimmunity to HSP60 contributes to, and HSP60 peptide treatment partially 1 
reverses, metabolic disturbances in a murine obesity model. 2 
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Legends to Figures 1 
 2 
Figure 1. Effect of HFD on weight gain, metabolism and auto-immunity to HSP60. 3 
Groups of mice (n=7) were fed HFD or ND for 16 weeks. (A) Body weights (p=0.007) and (B) 4 
epididymal fat pad weights (p=0.004) were significantly increased by HFD. (C) Circulating 5 
LDL/VLDL levels were also significantly increased (p=0.005). (D) Mouse HSP60 levels 6 
measured in serum samples by ELISA were significantly higher in HFD compared to ND fed 7 
mice (p=0.039; n=19 each). (E) T cell proliferation (expressed relative to the medium alone 8 
negative control) increased significantly in HFD compared to ND splenoctes when stimulated 9 
by 0.1 µg/ml (p=0.013) or 10 µg/ml (p=0.038) of recombinant mouse HSP60. (F) Both anti-10 
HSP60 IgG1 and IgG2c circulating antibody levels were significantly elevated by HFD 11 
(pmax=0.008 for IgG1; pmax=0.00009 for IgG2c). 12 
 13 
Figure 2. Effect of HSP60 peptide treatment on obesity, metabolic dysfunction and auto-14 
immunity to HSP60 15 
(A) Mice (n=14) given HFD or HFD with HSP60 peptides  increased weight to the same extent 16 
relative to ND (p=0.000002 for HFD, p=0.00045 for HSP60) (B) Epididymal fat pad weights 17 
were similarly doubled by HFD or HFD with HSP60 peptides (p=0.0012 for HFD, p=0.00009 18 
for HSP60) (C) HFD increased LDL/VLDL (p=0.0003) and HDL levels (p=0.00045) and the 19 
HSP60 treatment significantly normalised LDL/VLDL levels (p=0.0088) but not HDL levels. 20 
(D) HFD significantly impaired glucose tolerance (p=3.4x10-18, 2-Way ANOVA) and the 21 
impairment was partially but significantly reversed by HSP60 peptide treatment (p=0.0079). 22 
In a subgroup (n=7 each): (E) No differences were found in insulin tolerance between the three 23 
groups. (F) From flow cytometry, epididymal stromal vascular fraction CD45+CD11b+F4/80+ 24 
macrophages were increased (p=0.013) and (G) CD45+CD3+CD4+CD25+Foxp3+ regulatory T 25 
12 
 
cells were decreased significantly (p=0.003) with HFD or HFD plus HSP60 peptides. (H) There 1 
was an increase in the level of anti-HSP60 IgG1 antibodies observed in both HFD groups, but 2 
only the increase in the peptide treatment group was significant (p=0.022) (I) Anti-HSP60 3 
IgG2c antibodies were increased in HFD mice, but this was significant only in the HFD alone 4 
group (p=0.048 for 1/16 dilution). 5 
 6 
 7 
